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Poster Session I S257effects included nausea, vomiting, diarrhea, dizziness and lighthead-
edness following doses 1 and 2. The patient underwent AuSCT and
achieved neutrophil engraftment on day +13 and platelet engraft-
ment on day +20.
Observations:Peak concentrations were proportional to dose. AUC
increased over the 3 days suggesting accumulation. Estimated clear-
ance on HD was 3-3.7 fold higher than clearance off HD. Cl/F and
V/F after dose 1 was comparable to published values while T1/2 is
longer. Maximum 40mg dose was effective and tolerated. Plerixafor
and filgrastim stimulated mobilization of HSC in the actively dia-
lyzed patient is feasible, well tolerated and results in adequate num-
bers of functional cells for use in AuSCT.142
LONG TERM ENGRAFTMENT IS ASSOCIATED WITH SURVIVAL AFTER AU-
TOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTI-
PLE MYELOMA
Bains, T., Lemieux, A., Abar, F., Maziarz, R.T., Chen, A.I. Knight Can-
cer Institute- Oregon Health and Science University, Portland, OR
The correlationwith long term engraftment on outcomes after au-
tologous transplantation is largely unknown. We conducted a retro-
spective analysis of 214 patients who underwent auto-SCT for
multiple myeloma from 1990 – 2009 and correlated long term en-
graftment of PBSC autografts (median CD34 dose 4.49; range
1.77-81.96) with outcomes. Patients who receivedmaintenance ther-
apy were not included in this analysis, and patients who relapsed
prior to assessment of engraftment were also excluded. Optimal en-
graftment was defined by NCI CTCAE grade 1 criteria for cytope-
nias (ANC$ 1,500/mm3, platelets$ 75,000/mm3, and hemoglobin
$ 10g/dL). The median age was 57 (range 31-76), and the median
follow-up was 2.9 years. At day 100, 40% of patients achieved opti-
mal engraftment, and 34% of patients had maintained these optimal
engraftment levels at 1 year. There were no significant differences in
gender, age, number of prior therapies, myelotoxic therapies (mel-
phalan, lenalidomide, or radiation), andCD34 dose between patients
with optimal vs sub-optimal engraftment. Cytogenetics and ISS
stage from diagnosis were not available in the majority of patients.
Performance status (KPS\90%) was associated with poor engraft-
ment at day 100 but not 1 year.
Engraftment at day 100 was not associated with outcome. How-
ever, patients with optimal engraftment at 1 year were observed to
have improved 3 year overall survival (89% vs 69%, p 5 0.05) but
not progression free survival (61% vs 62%). In our series, the major-
ity of patients did not achieve optimal long term engraftment after
auto-SCT in myeloma, and there appears to be a correlation of im-
paired long term engraftment with a deleterious effect on overall sur-
vival. Further analysis in larger data sets and other hematologic
malignancies to confirm this finding and to identify factors predictive
of long term engraftment is ongoing.143
PHASE IIA, OPEN-LABEL, RANDOMIZED, PHARMACOKINETIC COMPARA-
TIVE, CROSS-OVER STUDY OF MELPHALAN HCL FOR INJECTION (PRO-
PYLENE GLYCOL-FREE) AND ALKERAN FOR INJECTION FOR
MYELOABLATIVE CONDITIONING IN MULTIPLE MYELOMA PATIENTS
UNDERGOING AUTOLOGOUS TRANSPLANTATION
Aljitawi, O.S.1,2, Ganguly, S.1,2, Abhyankar, S.1,2, Wolfe, K.2,
Daniels, K.2, Ferree, M.3, Marks, R.3, Kramer, W.4, Pipkins, J.D.5,
McGruirk, J.P.1,2 1University of Kansas Medical Center; 2University of
Kansas Cancer Center; 3Clinipace Worldwide; 4Kramer Consulting
LLC; 5CyDex Pharmaceuticals, Inc. (A Ligand Company)
Background: Though high-dose melphalan and autologous trans-
plantation is a standard procedure in transplant eligible multiple my-
eloma patients. Themarketed formulation of melphalan, Alkeran for
Injection (Alkeran), has marginal solubility and limited chemical sta-
bility upon reconstitution. Alkeran uses propylene glycol as a co-sol-
vent, which has been reported to cause complications including renal
dysfunction and arrhythmias. Propylene Glycol-Free MelphalanHCL for Injection (PG-free Melphalan) is a reformulation of Al-
keran. It incorporates Captisol, a specially modified cyclodextrin,
to replace the co-solvents and improve stability. This abstract sum-
marizes the ultimate findings from this study after enrollment of all
planned patients.
Methods: This is a phase IIa, open-label, randomized, cross-over
design bioequivalence study. In this study, both the compartmental
and non-compartmental pharmacokinetics (PK) of PG-freeMelpha-
lan and Alkeran were assessed in the same MM patients undergoing
transplantation. Patients received both drug products in alternating
dosing day fashion and were their own control for PK comparison.
Furthermore, the safety and tolerability of high-dose melphalan
HCL and rates of myeloablation and subsequent engraftment were
determined in all patients.
Results: 24 patients, 11 females and 13males, were enrolled between
2/4/2010 and 05/16/2011 at TheUniversity of KansasMedical Cen-
ter and Cancer Center. All patients achieved myeloablation followed
by successful engraftment. Median time to myeloablation was 6 days
post the start of preparative regimen (range 3-8 days). Median time
to neutrophil engraftment was day +9.5 post transplant (range: 9-
12). No additional toxicities were reported with PG-freeMelphalan.
The following events occurred more frequently ($2 difference)
when Alkeran was given first (edema, headache, dysguesia, rash, bun-
dle branch block,) and the following events occurredmore frequently
($2 difference) when PG-free Melphalan was given first (dizziness).
PK analysis showed PG-free Melphalan was bioequivalent with Al-
keran and also revealed that Cmax and AUC were somewhat higher
after PG-free Melphalan.
Conclusions: PG-free Melphalan resulted in successful myeloabla-
tion and subsequent engraftment with no immediate infusion-re-
lated toxicity and no additional overall transplant-related toxicity.
PG-free Melphalan was bioequivalent to Alkeran while also demon-
strating a marginally higher systemic drug exposure.144
AN INNOVATIVE APPROACH TO AUTOLOGOUS STEM CELL COLLECTION
IN THE PEDIATRIC PATIENT
Peltz, A.C., Law, D.E., Giller, R.H. Children’s Hospital Colorado,
Aurora, CO
Autologous stemcell collection in the pediatric patient can be a chal-
lenging and expensive endeavor. Our institution has created a novel,
systematic procedure that has created a safe and efficient collection.
Using outpatient Interventional Radiology, we place two turbo flow
PICC lines with imaging –guided percutaneous technique centrally
in patients that are greater than 30 kg. In patients under 30 kg, we
are able to use double lumen broviacs or a single turbo flow PICC
and the existing central line (I.e. single lumen mediport or broviac).
Collection then takes place in our outpatient Apheresis Center without
sedation of the patient. We have successfully collected more than 54
pediatric patients, with differing diagnoses, using these methods since
the end of September 2008. We have had no documented line infec-
tions of the temporary PICC lines. This method allows for the pediat-
ric patient to remain an outpatient, with a low morbidity procedure,
but optimizing the stem cell collection process.CLINICAL CELLULAR THERAPY145
THE USE OF BONE MARROW DERIVED MESENCHYMAL STROMAL CELLS
FOR TREATMENT OF PATIENTS WITH MULTIPLE SCLEROSIS AND NEU-
RODEGENERATIVE DISORDERS – ACHIEVEMENTS AND FUTURE GOALS
Slavin, S., Brodie, C. International Center for Cell Therapy & Cancer Im-
munotherapy (CTCI), Tel Aviv, Israel; Bar-Ilan University, Ramat-Gan,
Israel
Future treatment of multiple sclerosis (MS) aims at restoringmye-
lination and neurological functions as well as re-induction of self-tol-
erance. We studied the role of mesenchymal stromal stem cells
(MSC), known to be anti-inflammatory on the one hand and
S258 Poster Session Imulti-potent on the other, in experimental autoimmune encephalitis
(EAE), and found that treatment of mice with bone marrow derived
MSCs resulted in significant suppression of anti-self reactivity and
improved clinical and pathological disease manifestations. Using
green fluorescent donors, we documented that in addition to down
regulation of autoimmunity, neural differentiation of these cells
may occur in vivo. These observations suggested that treatment
with MSCs might be used for immune regulation and neuroprotec-
tion for patients with MS. Our preliminary results of a phase I/II
open clinical trial to evaluate the feasibility and safety of intrathecal
and intravenous administration of autologous bone marrow derived
MSCs in patients with severe MS failing conventional modalities
suggested that treatment with MSCs is feasible, safe and potentially
effective. No major side effect were developed or reported during
a follow up period of nearly 4 years. Based on our successful prelim-
inary pilot study in 13 patients with MS and 14 with ALS, a total of
.150 patients were treated with autologous bone marrow derived
MSCs, mostly.100 patients withMS alone were treated at our cen-
ter with MSCs administered partially intrathecally (106 MSC/Kg)
and additional 5 - 10x105/Kg intravenously. The treatment was un-
eventful with headache due to lumbar puncture being the most fre-
quent complaint (70%) and self-limited subfebrile temperature in
25% and no serious side effect. A total of 60 % of patients reported
improved outcome, in some with very significant objective improve-
ment of disease manifestations with subjective and objective im-
provement of EDSS score. More recently, we have discovered
a new proprietary technology which allows differentiation of both
bone marrow, adipose tissue derived and cord/placenta derived
MSCs into neural stem cells, motor neurons, dopaminergic neurons,
astrocytes and myelin basic protein secreting oligodendrocytes that
in principle may be used to induce remyelination. These results sug-
gest that treatment with MSCs may provide the most suitable ap-
proach for treatment of MS, which could also be applicable for
treatment of other neurodegenerative disorders.146
AVOIDING THE NEED FOR CLINICAL-GRADE OKT3: EX VIVO EXPANSION
OF T CELLS USING ARTIFICIAL ANTIGEN PRESENTING CELLS GENETI-
CALLY MODIFIED TO CROSS-LINK CD3
Ang, S.O., Maiti, S.N., Hartline, C., Olivares, S., Huls, H.,
Champlin, R., Cooper, L.J.N. University of Texas MD Anderson Cancer
Center
T-cell immunotherapy protocols rely on activation for sustained
proliferation in the ex vivo expansion of T cells to achieve clinically
meaningful numbers for human applications. We have successfully
expanded T cells using a robust platform technology based on
K562 cells genetically modified to function as artificial antigen pre-
senting cells (aAPC) for the numeric expansion of T cells. An aAPC
clone (clone #4) was engineered to have enforced co-expression of
CD64, CD86, membrane-bound interleukin (IL)-15, and CD137L
(41BBL). Mouse anti-human CD3 (OKT3) monoclonal antibody
can be loaded (bound by CD64) onto the aAPC to cross-link CD3
triggering ex vivo T-cell propagation. However, as clinical-grade
Orthoclone OKT3 (muromonab from Ortho Biotech) is no longer
available we generated a genetic approach to avoid the need to
load OKT3. This was accomplished by heterologous fusion of the
scFv region from OKT3 mAb to a drug resistance gene cassette
(C3hygro) and enforcing expression under selection with hygromycin
B.We initially expressed the C3hygro on tumor cells (e.g.,MB-MDA-
231 breast cancer cell line) and demonstrated with time-lapse video
microscopy that C3hygro+ tumor cells could be efficiently killed by
primary humanT cells. This is similar in principle to the mechanism
of action for bi-specific antibodies whereby T cells are brought into
contact with antigen+ tumor cells, as our C3hygro+ tumor cells can be
killed by previously unmodified T cells. We then adapted aAPC
clone 4 to express C3hygro to generate a cellular platform for the
non-specific propagation of T cells. These aAPC (K562OKT3) co-ex-
press the recognition domain of OKT3 in addition to the desired T-
cell co-stimulatory molecules. T cells propagated using g-irradiated
K562OKT3 aAPC similar to OKT3-loaded clone #4 aAPC have com-
parable phenotype by flow cytometric analysis. The use of K562 is
clinically appealing as we have generated master cell banks underINDs based on this cell line functioning as aAPC for human applica-
tion. Indeed, the development of K562OKT3 aAPC appears to be
a useful substitute for clinical protocols dependent on clinical-grade
OKT3. In summary, we report our recent efforts to generateOKT3-
based reagents K562OKT3 and C3hygro, useful for both clinical and
research applications.147
CO-TRANSPLANTATION OF POOLED CORD BLOOD (CB) THIRD-PARTY
UNIT, HLA-BLIND, CD34+ SELECTED CBU WITH A SINGLE 4-6/6 HLA-
COMPATIBLE CBU FOR ALLOGENEIC SCT IMPROVES ENGRAFTMENT
TIME
Peltier, L., Monczak, Y., Laneuville, P. McGill University, Montreal,
QC, Canada
Finding an HLA-compatible cord blood unit (CBU) containing
sufficient cells to ensure engraftment remains a significant obstacle
to the widespread adoption of cord blood grafts for allogeneic stem
cell transplantation in adults. This limitation can be overcome, as is
current practice, by co-transplanting two or three HLA-compatible
CBUs. This approach however is associated with increased graft pro-
curement expenses, and reduced probability of findingmore than one
compatible cord blood unit (CBU). Other approaches in develop-
ment include in vitro expansion and intraosseous infusion. We have
developed an alternative approach with the aim of increasing graft
cell content by creating third-party support fromCBUs that are con-
sidered to be too small for banking and that are normally discarded.
We prospectively collected these smaller CBUs and then developed
a rapid thawing method allowing the pooling of CBUs blinded to
HLA followed by CD34+ selection, to create a third-party graft for
allogeneic stem cell transplantation in adults. We report the results
on the first four high risk patients transplanted in a phase I/II trial
at our institution where the primary endpoint is time to engraftment.
All four patients received a 4/6 or 5/6HLAcompatibleCBUcontain-
ing 2.5 to 2.9 x10e7NC/Kg followedwithin2hours by the infusionof
the third-party graft after Flu-BuCy2 conditioning. All patients had
100% matched CBU chimerism at day +14 and the mean nucleated
cells (NC) engraftment was 19.7 days. Three patients were alive at
day +100 and one patient died at day +28 of acute relapse.
Table. Engraftment Time of the Match CBU
CD34 CD34Pt # DiagnosisAge
(Sexe)Weight
(Kg)HLA
Match(x10e5/kg)
Matched
CBU(x10e5/kg)
Third-Party
CBUsNC $0.5 
10e9/L1 NHL 41 (M) 81 4/6 1.1 3.0 D +152 CML 30 (M) 56 5/6 0.67 2.0 D +263 AML 32 (F) 88 4/6 1.63 2.5 D +184 ALL 57 (F) 72 5/6 1.3 1.9 D +21These results demonstrate that increasing the number ofHSC to sup-
port a$ 4/6HLA compatible CBU using third-party cells from pooled
HLAblindCBUs is safe, feasible, and results in rapid engraftment com-
pared to single CBU transplants. The advantage of this approach is that
it may be possible to obtain engraftment times comparable to multi-
matched CBU transplants, without having to find more than one com-
patible CBU, while salvaging otherwise discarded CBUs.148
CD8aa+ T CELLS, A NEW MEMORY T CELL COMPARTMENT
Magalhaes, I.1, Maeurer, M.J.1,2 1Karolinska Institutet, Stockholm, Swe-
den; 2Karolinska Institutet, Stockholm, Sweden
Adoptive T cell therapy is based on the genetic introduction of T
cell receptor (TCR) a- and b-chains to redirect effector T cell spec-
ificity. This is a well-established approach to generate ex vivo large
amounts of effector cells with defined specificity. The adoptive trans-
fer of high affinity CMV- and EBV- specific MHC-I restricted
